HTG EdgeSeq Oncology Biomarker Panel
Profile tumor samples in order to identify therapeutic targets and drug response markers using an NGS-based gene expression assay powered by the HTG EdgeSeq chemistry.
Thousands of genes (2,560), 24 groups and pathways
Includes Key Drug Targets
Additional Features | Benefits
- Low sample input | Consume only a single 5 µm FFPE tissue section
- Results in 36 hours | Gain insights faster with minimal hands-on manipulation
- Rapid alignment and data assembly | Obtain quantitative gene expression from sequence data in 30 minutes
The routine use of complex molecular profiling is enabled by the portfolio of automated HTG EdgeSeq products, which includes the HTG EdgeSeq Oncology Biomarker Panel.
Achieve consistent and reproducible performance through automation
Figure 1. To demonstrate robust chemistry and automation, 25 ng of universal RNA was processed using the HTG EdgeSeq Oncology Biomarker Panel across 3 days and 3 HTG EdgeSeq systems. Pearson correlation, r, averaged 0.97 for technical replicates (A), 0.985 for day-to-day replicates (B) and 0.988 for instrument vs instrument replicates (C). Data was log(2) transformed and correlation plots were prepared.
Gain the most from samples with minimal sample utilization
Figure 2. To measure the sensitivity of the assay, titration experiments were performed to (1) establish linearity (not shown) and (2) determine sample input limitations. 4-point titrations were performed with total RNA (A) and a human cell line (B). Fold expression changes remained consistent across the titration series through excellent correlation as measured by Pearson correlation, r.
Generate comprehensive data from very small sample inputs
Figure 3. Three types of FFPE tissue were processed with the HTG EdgeSeq Oncology Biomarker Panel at two sample inputs, 12.5 mm2 and 1.56 mm2 and sequenced on the Illumina MiSeq sequencing platform running v3 reagent chemistry. Across all sample types, data correlations between the two input amounts remained above 0.98 as measured by Pearson correlation, r.
Generate high quality tumor profiles from FFPE through extraction-free chemistry
Figure 4. Breast, Colon, Lung and Prostate FFPE tissue were processed with the HTG EdgeSeq Oncology Biomarker Panel. Sequencing was performed on the Illumina MiSeq instrument running v3 reagent chemistry. Data was first normalized against all reads per sample, and relative (%) expression measured across tissue types.
|Sample Type||Sample Input|
|FFPE Tissue||A single 5 µm FFPE tissue section|
|Cells||> 3,000 cells|
|Extracted RNA||> 25 ng|
ACTB, EE1G, OAZ1, RPL6, SOD1
ATP5F1, GAPDH, PPIA, RPS7, TBP
DDX5, NCL, RPL38, SLC25A3, YWHAZ
|Negative||5 ANT probes|
|Positive||4 POS1 assay controls|
|916-002-208||HTG EdgeSeq Oncology Biomarker Panel (2x8)|
|916-002-008||HTG EdgeSeq Oncology Biomarker Panel (4x8)|
|916-002-224||HTG EdgeSeq Oncology Biomarker Panel (1x24)|
|916-002-024||HTG EdgeSeq Oncology Biomarker Panel (4x24)|
|916-002-096||HTG EdgeSeq Oncology Biomarker Panel (1x96)|
|916-002-308||HTG EdgeSeq Oncology Biomarker Panel (2x8)|
|916-002-108||HTG EdgeSeq Oncology Biomarker Panel (4x8)|
|916-002-324||HTG EdgeSeq Oncology Biomarker Panel (1x24)|
|916-002-124||HTG EdgeSeq Oncology Biomarker Panel (4x24)|
2 – 4 million aligned sequencing recommended per sample are recommended.
Learn more about HTG EdgeSeq products and chemistry
HTG's GenomeWeb webinar: Expression-based Profiling of Challenging FFPE Tumor Samples
For Research Use Only. Not for use in diagnostic procedures.